NEWS HIGHLIGHTS
Published Studies Related to Ipratropium and Albuterol (Albuterol / Ipratropium Inhalation)
High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. [2009.08]
OBJECTIVE: To assess the use of high-dose continuous levalbuterol (LEV), the single active (R)-enantiomer of racemic albuterol (RAC), in the treatment of status asthmaticus... CONCLUSIONS: Substituting high-dose continuous LEV for RAC did not reduce the time on continuous therapy and had similar adverse effects in children who had failed initial treatment with RAC.
A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease. [2008.08]
The Federal Drug Administration (FDA) approved the use of Fluticasone 250 microg/Salmeterol 50 microg 1 puff bid for maintenance therapy in patients with COPD associated with chronic bronchitis. Short-acting beta agonists (SABA) have been the recommended rescue medication; however, previous studies have shown that combination short-acting Albuterol (alb) /Ipratropium bromide (IB) has superior bronchodilator properties to albuterol alone in patients with COPD...
Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. [2008.08]
BACKGROUND: The potential of anticholinergics to provide bronchodilatory benefits over short-acting beta(2)-agonists (SABA) alone in patients with moderate-to-severe persistent asthma has not been well defined... CONCLUSION: IB+ALB resulted in significantly greater improvement in FEV(1) and longer duration of response compared to ALB alone in patients with moderate-to-severe persistent asthma (Trial number: 1012.50; ClinicalTrial.gov NCT00096616).
Equivalence of a single saline nebulised dose of formoterol powder vs three doses of nebulised Albuterol every twenty minutes in acute asthma in children: a suitable cost effective approach for developing nations. [2008.07]
CONCLUSIONS: Single dose nebulised Formoterol Fumarate (dry powder) in sterile saline solution, as depicted in this trial, is equivalent to three doses of Albuterol every twenty minutes for one hour in acute asthma in children, simplifying acute care management and at one fifth of medication costs. A pursuit of simpler and more cost effective approaches is found wanting in developing nations with depressed economies and unique cultural and socio-medical contexts; also, in countries where pharmaco-economics orients quality of health policies, novel approaches like this are worth exploring.
[Efficacy of pulmicort suspension plus salbutamol and ipratropium bromide for management of acute asthma exacerbation in children: a comparative study.] [2008.03]
OBJECTIVE: To evaluate the efficacy of 3 commonly used protocols for management of acute exacerbation of asthma in children... CONCLUSION: Nebulized medicine is one of the best means for management of acute asthma exacerbation in children, and inhalation of budesonide suspension plus salbutamol and ipratropium bromide can effectively relieve the asthmatic symptoms in these children with good compliance and convenient administration.
Clinical Trials Related to Ipratropium and Albuterol (Albuterol / Ipratropium Inhalation)
A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation [Recruiting]
This is a double blind, controlled clinical trail testing whether three doses of 1. 25 mg of
nebulized levalbuterol in combination with three doses of 0. 5mg of nebulized ipratropium
will lead to greater bronchodilation than that achieved by three doses of nebulized 1. 25 mg
of levalbuterol alone every 20 minutes.
The primary hypothesis of this study is that three doses of 1. 25 mg of nebulized
levalbuterol in combination with three doses of 0. 5mg of nebulized ipratropium will lead to
greater bronchodilation than that achieved by three doses of nebulized 1. 25 mg of
levalbuterol alone every 20 minutes. The secondary hypothesis is that the treatment
combination of levalbuterol and ipratropium will lead to fewer hospitalizations than
levalbuterol alone in patients with acute asthma exacerbation. Other secondary objectives
include (1) evaluating the relationship between baseline (S)- albuterol levels and (R)-
albuterol levels on presentation and FEV1, (2) the relationship between baseline (S)-
albuterol levels and (R)- albuterol levels on presentation and change in FEV1,(3) time to
event analysis for an improvement of 15%, 20%, 30%, 40%, and 50% in FEV1 from initial
presentation value, (4) analysis of FEV1 at discharge.
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. [Recruiting]
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and
beta-agonist pharmacology in preclinical studies, both pharmacologies being of long
duration. If reproduced in man, GSK961081 has the potential to deliver a medicine that can
be given once daily. The bronchodilatation after inhalation of single doses of GSK961081
alone and in the presence of the short acting beta agonist salbutamol and the short acting
muscarinic antagonist, ipratropium bromide will be measured in this study. Any residual
bronchodilatation post-inhalation of GSK961081 and demonstrated by addition of salbutamol or
ipratropium bromide may provide an indirect assessment of the beta-agonist and
antimuscarinic components of GSK961081.
Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable COPD [Not yet recruiting]
Some patients with chronic obstructive pulmonary disease (COPD) take nebulised treatments to
ease the symptom of breathlessness, including the drug ipratropium. Nebulised bronchodilator
drugs are taken up to 4 times through the day, and this can take up to 15 minutes each time.
Although the treatment isbe effective, patients report that the time taken to set-up and use
the nebuliser can be a disincentive to regular use. By contrast, an inhaler device is easy
to use following appropriate instruction, and takes only a few seconds to administer.
Inhaled tiotropium is a once daily treatment taken by inhaler which has been shown to be
effective in COPD. We wish to assess whether inhaled Tiotropium as effective as nebulised
ipratropium in patients with stable chronic obstructive pulmonary disease.
Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD) [Recruiting]
This study was designed to test the following hypothesis:
The 3-min constant rate step test and the 3-min constant rate shuttle walk test will be
sensitive to detect improvement in exertional dyspnea following acute bronchodilation in
patients with COPD.
Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room. [Recruiting]
To determine whether adding nebulized inhaled steroids to the standard care of acutely ill
ED patients with refractory acute asthma helps improve FEV1 and decrease the need for
hospitalization.
|
